Tau antibody 77G7 targeting microtubule binding domain suppresses proteopathic tau to seed tau aggregation.

These findings indicate that 77G7 can effectively suppress the seeding activity of AD O-tau and thus could be developed as a potential immunotherapeutic drug to inhibit the propagation of tau pathology in AD and related tauopathies.